66549-07-3Relevant academic research and scientific papers
Towards dual inhibitors of the MET kinase and WNT signaling pathway; Design, synthesis and biological evaluation
Lien, Vegard Torp,Kristiansen, Margrethe Konstanse,Pettersen, Solveig,Haugen, Mads Haugland,Olberg, Dag Erlend,Waaler, Jo,Klaveness, Jo
, p. 37092 - 37100 (2019/11/25)
Both the kinase MET and the WNT signaling pathway are attractive targets in cancer therapy, and synergistic effects have previously been observed in animal models upon simultaneous inhibition. A strategy towards a designed multiple ligand of MET and WNT signaling is pursued based on the two hetero biaryl systems present in both the MET inhibitor tepotinib and WNT signaling inhibitor TC-E 5001. Initial screening was conducted to find the most suitable ring systems for further optimization, whereas a second screen explored modifications towards pyridazinones and triazolo pyridazines. Up to 54% reduction of WNT signaling activity at 10 μM concentration was achieved, however, only low affinities towards MET were observed. Overall, the thiophene substituted pyridazinone 40 was the best dual MET and WNT signaling inhibitor, with a 17% and 19% reduction of activity, respectively. Although further optimizations are needed to achieve more potent dual inhibitors, the strategy presented herein can be valuable towards the development of a dual inhibitor of MET and WNT signaling.
Novel Hydrazinone-substituted Pyrimidine Derivatives and Use Thereof
-
, (2018/05/29)
The present invention relates to a pyrimidine derivative substituted with novel hydrazine or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and to a pharmaceutical composition for preventing or treating hyperproliferative disorders, which comprise same as an active ingredient. The present invention can be effectively used as a treatment agent for various hyperproliferative disorders related to excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy by efficiently inhibiting c-Met tyrosine kinase activity.
Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors
Kang, Seung-Tae,Kim, Eun-Young,Archary, Raghavendra,Jung, Heejung,Park, Chi Hoon,Yun, Chang-Soo,Hwang, Jong Yeon,Choi, Sang Un,Chae, Chonghak,Lee, Chong Ock,Kim, Hyoung Rae,Ha, Jae Du,Ryu, Dohyun,Cho, Sung Yun
supporting information, p. 5093 - 5097 (2014/12/11)
We report a series of phenyl substituted pyridazin-3-ones substituted with morpholino-pyrimidines. The SAR of the phenyl was explored and their c-Met kinase and cell-based inhibitory activity toward c-Met driven cell lines were evaluated. Described herein
